Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000134.xml
CC BY-NC-ND 4.0 · Diabetologie und Stoffwechsel 2021; 16(02): 149-161
DOI: 10.1055/a-1386-0011
DOI: 10.1055/a-1386-0011
Übersicht
Hundert Jahre – Insulin bleibt aktuell und notwendig
Insulin – 100 years and still relevant
Zusammenfassung
In der Behandlung des Typ-1-Diabetes ist die Therapie mit Insulin auch 100 Jahre nach seiner Entdeckung weiterhin eine lebensnotwendige Therapie. Der pharmakologische Fortschritt hat die Behandlung erheblich erleichtert und nähert sich der physiologischen Insulin-Sekretion zunehmend an. In der Behandlung des Typ-2-Diabetes hingegen ist die Insulin-Therapie bei den meisten Patienten zunächst nicht notwendig. Lebensstil-Interventionen und moderne Nicht-Insulin Antidiabetika können häufig zu einer lang andauernden Kontrolle der Erkrankung führen. Die Heterogenität des Typ-2-Diabetes führt jedoch dazu, dass einige Patienten früh von einer Insulin-Therapie profitieren. Auch beim Typ-2-Diabetes können moderne Insulin Präparate die Insulin-Behandlung deutlich erleichtern, auch in Kombination mit anderen Antidiabetika. Einleitung und Begleitung einer Insulin-Therapie gehören somit weiterhin zu den Kernaufgaben der Diabetologie.
Abstract
Even 100 years after the first injection, insulin therapy remains vital in the treatment of type 1 diabetes. Pharmacologic innovations have facilitated insulin therapy and narrowed the gap to physiological insulin secretion. In type 2 diabetes insulin treatment is not required in most patients early after diagnosis. Modern antidiabetics and lifestyle therapy can lead to a long standing control of the disease. However, type 2 diabetes is a heterogenous disease and a patients with a deficit in insulin secretion benefit from an early initiation of insulin supplementation. Also combination with other antidiabetics has evolved. Therefore indicating and supporting insulin treatment remains a core component of diabetology.
Publication History
Received: 08 January 2021
Accepted: 08 February 2021
Article published online:
01 March 2021
© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Hegele RA, Maltman GM. Insulin’s centenary: the birth of an idea. Lancet Diabetes Endocrinol 2020; 8: 971-977
- 2 Fullerton B, Siebenhofer A, Jeitler K. et al Short-acting insulin analogues versus regular human insulin for aults with type 1 diabetes mellitus (Review). Cochrane Database of Systematic Reviews 2016; 6: CD012161
- 3 Nørgaard K, Sukumar N, Rafnsson SB. et al Efficacy and Safety of Rapid-Acting Insulin Analogs in Special Populations with Type 1 Diabetes or Gestational Diabetes: Systematic Review and Meta-Analysis. Diabetes Ther 2018; 9: 891-917
- 4 Mathieu C, Gillard P, Benhalima K. Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nat Rev Endocrinol 2017; 13 (07) 385-399
- 5 Danne T, Heinemann L, Bolinder J. New Insulins, Biosimilars, and Insulin Therapy. Diabetes Technol Ther 2019; 21 (Suppl. 01) S57-S78
- 6 Laranjeira FO, de Andrade KRC, Figueiredo ACMG. et al Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials. PLoS ONE 2018; 13 (04) e0194801
- 7 Kerr D, Wizemann E, Senstius J. et al Stability and Performance of Rapid-Acting Insulin Analogs Used for Continuous Subcutaneous Insulin Infusion: A Systematic Review. J Diabetes Sci Technol 2013; 7 (06) 1595-1606
- 8 Evans M, Ceriello A, Danne T. et al Use of fast-acting insulin aspart in insulin pump therapy in clinical practice. Diabetes Obes Metab 2019; 21 (09) 2039-2047
- 9 Senior P, Hramiak I. Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective. Can J Diabetes 2019; 43 (07) 515-523
- 10 Madenidou AV, Paschos P, Karagiannis T. et al Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Ann Intern Med 2018; 169 (03) 165-174
- 11 Aragon K, Elmaoued AA, Pham NT. et al Long-Acting Basal Insulins: A Review of the More Recently Approved Agents. Cardiol Rev 2019; 27 (05) 260-266
- 12 Horvath K, Jeitler K, Berghold A. et al Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; (02) CD005613
- 13 Cahn C, Miccoli R, Dardano A. et al New forms of insulin and insulin therapies for the treatment of type 2 diabetes. Lancet Diabetes Endocrinol 2015; 3: 638-652
- 14 Garg SK, Giordano D. New medications for the treatment of diabetes. Diabetes Technol Ther 2019; 21 (Suppl. 01) S160-S171
- 15 Marso SP, McGuire DK, Zinman B. et al Efficacy and Safety of degludec versus Glargine in Type 2 Diabetes. N Engl J Med 2017; 377: 723-32
- 16 Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes. A meta-analysis. Diabetes Res Clin Pract 2008; 81: 184-189
- 17 Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab 2009; 11: 372-378
- 18 Horvath K, Jeitler K, Berghold A. et al Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus (Review). Cochrane Database Syst Rev 2007;
- 19 Owens DR, Traylor L, Mullins P. et al Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100 U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy. Diabetes Res Clin Pract 2017; 124: 57-65
- 20 Russell-Jones D, Gall MA, Niemeyer M. et al Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials. Nutr Metab Cardiovasc Dis 2015; 25: 898-905
- 21 Rosenstock J, Cheng A, Ritzel R. et al More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT. Trial Diabetes Care 2018; 41: 2147-2154
- 22 Pan C, Jorge L, Gross JL. et al Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naıve Patients with Type 2 Diabetes Mellitus. Drugs R D 2016; 16: 239-249
- 23 Lasserson DS, Glasziou P, Perera R. et al Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia 2009; 52: 1990-2000
- 24 Lipska KJ, Parker MM, Moffet HH. et al Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes. JAMA 2018; 320 (01) 53-62
- 25 Rosenstock J, Bajaj HS, Janež A. et al Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. N Engl J Med 2020; 383: 2107-2116
- 26 Xie J, Li A, Li J. Advances in pH-Sensitive Polymers for Smart Insulin Delivery. Macromol Rapid Commun 2017; 38: 1700413
- 27 Rege NK, Phillips NFB, Weiss MA. Development of Glucose-Responsive “Smart” Insulin Systems. Curr Opin Endocrinol Diabetes Obes 2017; 24 (04) 267-278
- 28 Conner F, Pfiester E, Elliott J. et al Unaffordable insulin: patients pay the price. Lancet Diabetes Endocrinol 2019; 7 (10) 748
- 29 Kehlenbrink S, Jaacks LM, on behalf of the Boston Declaration signatories. Diabetes in humanitarian crises: the Boston Declaration. Lancet Diabetes Endocrinol 2019; 7: 590-592
- 30 Garrett TJ, Atkinson P, Quinlivan EP. et al Commercially Available Insulin Products Demonstrate Stability Throughout the Cold Supply Chain Across the U.S. Diabetes Care 2020; 43 (01) 1360-1362
- 31 Socal MP, Greene JA. Interchangeable Insulins – New Pathways for Safe, Effective, Affordable Diabetes Therapy. New Engl J Med 2020; 382: 981-983
- 32 Ilonen J, Lempainen J, Veijola R. The heterogeneous pathogenesis of type 1 diabetes mellitus. Nat Rev Endocrinol 2019; 15 (11) 635-650
- 33 Nathan DM, for the DCCT/EDIC Research Group*. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview. Diabetes Care 2014; 37: 9-16
- 34 The Diabetes Control and ComplicationsTrial (DCCT)/Epidemiology of DiabetesInterventions and Complications (EDIC) Study Research Group*. Intensive Diabetes Treatment andCardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study30-Year Follow-up. Diabetes Care 2016; 39: 686-693
- 35 Fullerton B, Jeitler K, Seitz M. et al Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus (Review). Cochrane Database Syst Rev 2014; 2014 (02) CD009122
- 36 Kähler P, Grevstad B, Almdal T. et al Targeting intensive versus conventional glycaemic control for type 1 diabetes mellitus: a systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ Open 2014; 4: e004806
- 37 Landgraf R. Impact of pancreas transplantation on diabetic secondary complications and quality of life. Diabetologia 1996; 39: 1415-1424
- 38 Gruessner A, Gruessner RWG. Pancreas Transplantation for Patients with Type 1 and Type 2 Diabetes Mellitus in the United States: A Registry Report. Gastroenterol Clin N Am 2018; 47: 417-441
- 39 Aref A, Zayan T, Pararajasingam R. et al Pancreatic transplantation: Brief review of the current evidence. World J Transplant 2019; 9 (04) 81-93
- 40 Vantyghem MC, de Koning EJP, Pattou F. et al Advances in β-cell replacement therapy for the treatment of type 1 diabetes. Lancet 2019; 394: 1274-1285
- 41 Tremmel DM, Mitchell SA, Sackett SD. et al Mimicking nature-made beta cells: recent advances towards stem cell-derived islets. Curr Opin Organ Transplant 2019; 24 (05) 574-581
- 42 Senior PA, Pettus JH. Stem cell therapies for Type 1 diabetes: current status and proposed road map to guide successful clinical trials. Diabet Med 2019; 36 (03) 297-307
- 43 Dayan CM, Korah M, Tatovic D. et al Changing the landscape for type 1 diabetes: the first step to prevention. Lancet 2019; 394: 1286-1296
- 44 Deutsche Diabetes Gesellschaft. S3-Leitlinie Therapie des Typ-1-Diabetes. AWMF-Registernummer: 057-013
- 45 Brown SA, Kovatchev BP, Raghinaru D. et al SixMonth Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. N Engl J Med 2019; 381 (18) 1707-1717
- 46 Boughton CK, Hovorka R. Is an artificial pancreas (closed-loop system) for Type 1 diabetes effective?. Diabet Med 2019; 36: 279-286
- 47 Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab 2012; 14: 780-788
- 48 Haahr H, Heise T. Fast‑Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences. Clin Pharmacokinet 2020; 59: 155-172
- 49 Nicolucci A, Ceriello A, Di Bartolo P. et al Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes. Diabetes Ther 2020; 11: 573-584
- 50 Evans M, Ceriello A, Danne T. et al Use of fast-acting insulin aspart in insulin pump therapy in clinical practice. Diabetes Obes Metab 2019; 21: 2039-2047
- 51 Beck RW, Bergenstal RM, Laffel LM. et al Advances in technology for management of type 1 diabetes. Lancet 2019; 394: 1265-1273
- 52 Nishimura H, Lizuka K, Takeda J. Protamine-containing insulin but not analog insulin and duration of insulin use are risk factors for the production of insulin autoantibodies in insulin-treated patients with diabetes mellitus. Endocrine J 2014; 61 (06) 635-640
- 53 Butt AJ, De Bruin ML, Bazelier MT. et al Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. Diabetologia 2017; 60: 1691-1703
- 54 Frandsen CS, Dejgaard TF, Madsbad S. et al Non-insulin pharmacological therapies for treating type 1 diabetes. Expert Opin Pharmacother 2018; 19 (09) 947-960
- 55 Tosur M, Redondo MJ, Lyons SK. Adjuvant Pharmacotherapies to Insulin for the Treatment of Type 1 Diabetes. Curr Diabetes Rep 2018; 18: 79
- 56 Dandona P, Mathieu C, Phillip M. et al Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2017; 5: 864-876
- 57 Paik J, Blair HA, Monaco K. et al Dapagliflozin: A Review in Type 1 Diabetes. Drugs 2019; 79: 1877-1884
- 58 Mathieu C, Van Den Mooter L, Eeckhout B. Empagliflozin in type 1 diabetes. Diabetes Metab Syndr Obes 2019; 12: 1555-1561
- 59 Taylor SI, Blau JE, Rother KI. et al SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks. Lancet Diabetes Endocrinol 2019; 7: 949-958
- 60 McCrimmon RJ, Henry RR. SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia 2018; 61: 2126-2133
- 61 Evans M, Hicks D, Patel D. et al Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes. Diabetes Ther 2020; 11: 37-52
- 62 Wang W, Liu H, Xiao S. et al Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes Ther 2017; 8: 727-738
- 63 Andersen A, Lund A, Knop FK. et al Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol 2018; 14 (07) 390-403
- 64 Mathieu C, Zinman B, Uddén Hemmingsson J. et al Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: the ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care 2016; 39: 1702-1710
- 65 Ahrén B, Hirsch IB, Pieber TR. et al Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the adjunct two randomized trial. Diabetes Care 2016; 39: 1693-1701
- 66 Nauck MA, Meier JJ. GLP-1 receptor agonists in type 1 diabetes: a magic bullet?. Lancet Diabetes Endocrinol 2020; 8 (04) 262-264
- 67 Vella S, Buetow L, Royle P. et al The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia 2010; 53 (05) 809-820
- 68 Petrie JR, Nishi Chaturvedi N, Ford I. et al Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5 (08) 597-609
- 69 Livingstone R, Boyle JG, Petrie JR on behalf of The REMOVAL Study Team. A new perspective on metformin therapy in type 1 diabetes. Diabetologia 2017; 60: 1594-1600
- 70 Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature 2019; 576: 51-60
- 71 Christensen AA, Gannon M. The Beta Cell in Type 2 Diabetes. Curr Diab Rep 2019; 19: 81
- 72 Ahlqvist E, Storm P, Käräjämäki A. et al Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018; 6 (05) 361-369
- 73 Zaharia OP, Strassburger K, Strom A et al for the German Diabetes Study Group. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 2019; 7 (09) 684-694
- 74 Nauck M, Gerdes C, Petersmann A. et al Definition, Klassifikation und Diagnostik des Diabetes mellitus: Update 2020. Diabetologie 2020; 15 (Suppl. 01) S9-S17
- 75 Jacobs E, Rathmann W. In: Deutscher Gesundheitsbericht Diabetes 2020. Deutsche Diabetes Gesellschaft und diabetesDE (Hrsg). Verlag Kirchheim + Co GmbH, Mainz 2019, Seiten 9-16.
- 76 Müller TD, Finan B, Bloom SR. et al Glucagon-like peptide 1 (GLP-1). Mol Metab 2019; 30: 72-130
- 77 Nauck MA, Meier JJ. Management of endocrine disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?. Eur J Endocrinol 2019; 181 (06) R211-R234
- 78 Lim S, Kim KM, Nauck MA. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns. Trends Endocrinol Metab 2018; 29 (04) 238-248
- 79 Abd El Aziz MS, Kahle M, Meier JJ. et al A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab 2017; 19 (02) 216-227
- 80 Zelniker TA, Wiviott SD, Raz I. et al SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393: 31-39
- 81 Zelniker TA, Wiviott SD, Raz I. et al Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation 2019; 139 (17) 2022-2031
- 82 Kramer C, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2013; 1: 28-34
- 83 van Raalte R, Verchere CB. Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest?. Diabetes Obes Metab 2017; 19: 1205-1213
- 84 Koufakis T, Karras SN, Zebekakis P. et al Should the last be first? Questions and dilemmas regarding early short-term insulin treatment in Type 2 Diabetes Mellitus. Expert Opin Biol Ther 2018; 18 (11) 1113-1121
- 85 Khunti K, Kosiborod M, Ray KR. Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?. Diabetes Obes Metab 2018; 20: 1337-1341
- 86 Monnier L, Colette C, Schlienger JL. et al Glucocentric risk factors for macrovascular complications in diabetes: Glucose 'legacy' and 'variability'-what we see, know and try to comprehend. Diabetes Metab 2019; 45 (05) 401-408
- 87 Laiteerapong N, Ham SA, Gao Y. et al The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care 2019; 42: 416-426
- 88 Peyrot M, Rubin RR, Lauritzen T et al. For the International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005; 28 (11) 2673-2679
- 89 Young-Hyman D, de Groot M, Hill-Briggs F. et al Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016; 39: 2126-2140
- 90 Holmes-Truscott E, Pouwer F, Speight J. et al Assessing Psychological Insulin Resistance in Type 2 Diabetes: a Critical Comparison of Measures. Curr Diab Rep 2017; 17: 46
- 91 Khunti S, Khunti K, Seidu S. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. Ther Adv Endocrinol Metab 2019; 10: 2042018819844694
- 92 Landgraf R, Aberle J, Birkenfeld AL. et al Therapie des Typ-2-Diabetes. Diabetologie 2020; 15 (Suppl. 01) S65-S92
- 93 Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (Hrsg). Nationale VersorgungsLeitlinie Typ-2-Diabetes. Langfassung. 2. Auflage, 2020, Konsultationsfassung. AWMF-Register-Nr.: nvl-001. www.diabetes.versorgungsleitlinien.de
- 94 Maiorino MI, Chiodini P, Bellastella G. et al Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2017; 40: 614-624
- 95 Maiorino MI, Chiodini P, Bellastella G. et al The good companions: insulin and glucagon-like peptide-1 receptor agonist. Diab Res Clin Pract 2019; 154: 101-115
- 96 Gentilella R, Pechtner V, Corcos A. et al Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?. Diabetes Metab Res Rev 2019; 35: e3070
- 97 Giugliano D, Chiodini P, Maiorino MI. et al Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrine 2016; 51: 417-428
- 98 Fullerton B, Siebenhofer A, Jeitler K. et al Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus. Cochrane Database System Rev 2018; 12: CD013228
- 99 Pieber TR, Svehlikova E, Brunner M. et al Fast-acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart. Diabetes Obes Metab 2019; 21 (09) 2068-2075
- 100 Heise T, Linnebjerg H, Coutant D. et al Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. Diabetes Obes Metab 2020; 22: 1789-1798
- 101 Leohr J, Dellva MA, Coutant DE. et al Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study. Clin Pharmacokinet 2020; 59 (12) 1601-1610
- 102 Holman RR, Thorne KI, Farmer AJ. et al Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. N Engl J Med 2007; 357: 1716-1730
- 103 Bretzel R, Eckhard M, Landgraf W. et al Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents. Basal or prandial insulin? The APOLLO trial and beyond. Diabetes Care 2009; 32 (Suppl. 02) S260-S265
- 104 Pugliese G, Penno G, Natali A. et al Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on „The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function“. Nutr Metab Cardiovasc Dis 2019; 29 (11) 1127-1150
- 105 de Boer IH, Zelnick L, Afkarian M. et al Impaired Glucose and Insulin Homeostasis in Moderate-Severe CKDJ. Am Soc Nephrol 2016; 27 (09) 2861-2871
- 106 Edridge CL, Dunkley AJ, Bodicoat DH. et al Prevalence and incidence of hypoglycaemia in 532 542 people with type 2 diabetes on oral therapies and insulin: a systematic review and meta-analysis of population based studies. PLoS One 2015; 10: e0126427
- 107 Kern W, Holstein A, Moenninghoff C. et al Self-reported Hypoglycaemic Events in 2 430 Patients with Insulin-treated Diabetes in the German Sub-population of the HAT Study. Exp Clin Endocrinol Diabetes 2017; 125 (09) 592-597
- 108 Müller N, Lehmann T, Klöss A. et al Changes in incidence of severe hypoglycaemia in people with type 2 diabetes from 2006 to 2016: analysis based on health insurance data in Germany considering the antihyperglycaemic medication. Diabet Med 2020; 37 (08) 1326-1332
- 109 van Meijel LA, de Vegt F, Abbink EJ. et al High prevalence of impaired awareness of hypoglycemia and severe hypoglycemia among people with insulin- treated type 2 diabetes: The Dutch Diabetes Pearl Cohort. BMJ Open Diab Res Care 2020; 8: e000935
- 110 Elliott L, Fidler C, Ditchfield A. et al Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes. Diabetes Ther 2016; 7 (01) 45-60
- 111 International Hypoglycaemia Study Group. Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2017; 40: 155-157
- 112 Heller SR, Buse JB, Ratner R. et al Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes. Diabetes Care 2020; 43: 398-404
- 113 Wysham C, Bhargava A, Chaykin L. et al Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA 2017; 318: 45-56
- 114 Philis-Tsimikas A, Klonoff DC, Khunti K. et al Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. Diabetologia 2020; 63 (04) 698-710
- 115 Silbert R, Salcido-Montenegro A, Rodriguez-Gutierrez R. et al Hypoglycemia Among Patients with Type 2 Diabetes: Epidemiology, Risk Factors, and Prevention Strategies. Curr Diab Rep 2018; 18 (08) 53
- 116 Lipska KJ, Warton EM, Huang ES. et al HbA1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging Study. Diabetes Care 2013; 36 (11) 3535-3542
- 117 Monnier L, Wojtusciszyn A, Molinari N. et al Respective Contributions of Glycemic Variability and Mean Daily Glucose as Predictors of Hypoglycemia in Type 1 Diabetes: Are They Equivalent?. Diabetes Care 2020; 43 (04) 821-827
- 118 Toschi E, Slyne C, Sifre K. et al The Relationship Between CGM Derived Metrics, A1C, and Risk of Hypoglycemia in Older Adults With Type 1 Diabetes. Diabetes Care 2020; 43 (10) 2349-2354
- 119 Thieu VT, Mitchell BD, Varnado OJ. et al Treatment and prevention of severe hypoglycaemia in people with diabetes: Current and new formulations of glucagon. Diabetes Obes Metab 2020; 22: 469-479